Milton Roach, MD
Internal Medicine · Little Rock, ARNPI 1922005974
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 882 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 882 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- GSK$1K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Amgen$1K
- Pfizer$934
- plus $5K from 46 others
What the payments were for
- Food & beverage$12,463100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,477 in reported general payments places this provider in the 95th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 200 | $159,442 |
| JardianceEmpagliflozin | 103 | $107,440 |
| MounjaroTirzepatide | 59 | $78,315 |
| JanuviaSitagliptin Phosphate | 99 | $73,663 |
| EliquisApixaban | 93 | $64,259 |
| OzempicSemaglutide | 41 | $53,808 |
| TrulicityDulaglutide | 45 | $42,448 |
| XareltoRivaroxaban | 31 | $30,224 |
| TradjentaLinagliptin | 41 | $29,965 |
| Repatha SureclickEvolocumab | 52 | $28,847 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $26,181 |
| LinzessLinaclotide | 27 | $20,303 |
| Nucynta ErTapentadol Hcl | 12 | $19,322 |
| QuliptaAtogepant | 18 | $19,209 |
| KerendiaFinerenone | 25 | $15,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $1,187 | $167,625224 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $192 | $144,731160 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,245 | $120,762104 claims |
| MerckJanuvia | $258 | $73,66399 claims |
| PfizerEliquis, Premarin | $934 | $69,449112 claims |
| Novo NordiskOzempic, Rybelsus | $481 | $65,48756 claims |
| AbbVieLinzess, Qulipta, Synthroid | $1,833 | $45,476150 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $1,444 | $35,62163 claims |
| Johnson & JohnsonXarelto | $259 | $30,22431 claims |
| BayerKerendia | $82 | $15,68125 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $7,73817 claims |
| Esperion Therapeutics, Inc.Nexletol | $54 | $5,60414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Little Rock
- Aaron StrobelLittle Rock$32K
- Jeremy DavisLittle Rock$17K
- Ritesh RampureLittle Rock$13K
- Michael CloudLittle Rock$10K
- Saul Rios HerreraLittle Rock$8K
- Zhangning ChenLittle Rock$8K
- Russell RoarkLittle Rock$7K
- Arpana EdalaLittle Rock$6K
- Srikanth VallurupalliLittle Rock$5K
- Devendra PatelLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.